Wave Life Sciences, Inc. (WVE): who owns it and who trades it
As of Nov 16, 2026, WVE insiders reported 45 open-market sales worth $15.8M and 5 purchases worth $82.6M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Chris Francis (See Remarks), with $7.1M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Wave Life Sciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns WVE
237 funds and institutions reported WVE shares worth $1.1B at the end of Q2 2026, about 95% of the company. The largest holder is Ra Capital Management, L.P. with 14.0%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 26.98M | 14.02% | $157M | No change |
| BlackRock, Inc. | 19.20M | 9.98% | $112M | +36% |
| GSK plc | 18.25M | 9.49% | $106M | No change |
| Maverick Capital Ltd | 10.28M | 5.34% | $59.7M | +1% |
| Driehaus Capital Management LLC | 5.44M | 2.83% | $31.6M | +0% |
| Primecap Management Co | 5.35M | 2.78% | $31.1M | +11% |
| 683 Capital Management, LLC | 4.95M | 2.57% | $28.8M | +1% |
| FMR LLC (Fidelity) | 4.92M | 2.56% | $28.6M | -5% |
| State Street Corp | 4.84M | 2.52% | $28.1M | +32% |
| Readystate Asset Management LP | 4.73M | 2.46% | $27.5M | – |
| M28 Capital Management LP | 4.59M | 2.39% | $26.7M | No change |
| Geode Capital Management, LLC | 3.87M | 2.01% | $22.5M | +8% |
| Two Sigma Investments, LP | 3.71M | 1.93% | $21.5M | +97% |
| Algert Global LLC | 2.82M | 1.46% | $16.4M | +114% |
| Qube Research & Technologies Ltd | 2.78M | 1.44% | $16.1M | +1680% |
| Squarepoint Ops LLC | 2.54M | 1.32% | $14.8M | +74% |
| Morgan Stanley | 2.42M | 1.26% | $14.1M | +78% |
| Vanguard Portfolio Management LLC | 2.11M | 1.10% | $12.3M | +79% |
| Pfizer Inc | 1.88M | 0.97% | $10.9M | No change |
| Millennium Management LLC | 1.81M | 0.94% | $10.5M | +86% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, WVE insiders reported $82.6M of open-market purchases and $15.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Adrian Rawcliffe | Director | Sale | 12,700 | $5.29 | $67.2K | Form 4 |
| Aug 11, 2026 | Heidi L Wagner | Director | Sale | 7,000 | $6.01 | $42.1K | Form 4 |
| Aug 11, 2026 | Ken Takanashi | Director | Sale | 3,864 | $6.01 | $23.2K | Form 4 |
| Aug 11, 2026 | Aik Na Tan | Director | Sale | 432 | $6.01 | $2.6K | Form 4 |
| Mar 30, 2026 | Ra Capital Management, L.P. +3 | Director | Purchase | 971,091 | $6.50 | $6.3M | Form 4 |
| Mar 27, 2026 | Ra Capital Management, L.P. +3 | Director | Purchase | 2.50M | $6.43 | $16M | Form 4 |
| Mar 26, 2026 | Ra Capital Management, L.P. +3 | Director | Purchase | 351,224 | $6.38 | $2.2M | Form 4 |
| Mar 26, 2026 | Ra Capital Management, L.P. +3 | Director | Purchase | 4.95M | $6.06 | $30M | Form 4 |
| Feb 26, 2026 | Chris Francis | See Remarks | Sale | 17,900 | $15.09 | $270K | Form 4 |
| Feb 26, 2026 | Chris Francis | See Remarks | Sale | 15,294 | $15.00 | $229K | Form 4 |
| Feb 9, 2026 | Kyle Moran | CFO | Sale | 3,588 | $13.45 | $48.3K | Form 4 |
| Feb 9, 2026 | Paul Bolno | CEO | Sale | 10,480 | $13.45 | $141K | Form 4 |
| Feb 9, 2026 | Chris Francis | See Remarks | Sale | 1,883 | $13.45 | $25.3K | Form 4 |
| Feb 9, 2026 | Chandra Vargeese | See Remarks | Sale | 3,228 | $13.45 | $43.4K | Form 4 |
| Jan 2, 2026 | Chris Francis | See Remarks | Sale | 1,295 | $16.70 | $21.6K | Form 4 |
| Jan 2, 2026 | Chris Francis | See Remarks | Sale | 8,080 | $15.92 | $129K | Form 4 |
| Dec 11, 2025 | GSK plc | 10% owner | Purchase | 1.47M | $19.00 | $27.9M | Form 4 |
| Dec 9, 2025 | Kyle Moran | CFO | Sale | 50,000 | $20.03 | $1M | Form 4 |
| Dec 9, 2025 | Kyle Moran | CFO | Sale | 36 | $20.25 | $729 | Form 4 |
| Dec 8, 2025 | Adrian Rawcliffe | Director | Sale | 42,000 | $15.00 | $630K | Form 4 |
| Dec 8, 2025 | Heidi L Wagner | Director | Sale | 7,000 | $14.00 | $98K | Form 4 |
| Dec 8, 2025 | Heidi L Wagner | Director | Sale | 7,000 | $13.00 | $91K | Form 4 |
| Dec 8, 2025 | Christian O Henry | Director | Sale | 42,000 | $12.75 | $536K | Form 4 |
| Dec 8, 2025 | Christian O Henry | Director | Sale | 30,000 | $18.02 | $541K | Form 4 |
| Dec 8, 2025 | Christian O Henry | Director | Sale | 15,000 | $14.07 | $211K | Form 4 |
| Dec 8, 2025 | Christian O Henry | Director | Sale | 6,445 | $12.75 | $82.2K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 21,000 | $12.75 | $268K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 25,000 | $15.00 | $375K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 20,000 | $12.75 | $255K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 17,230 | $15.00 | $258K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 15,000 | $12.75 | $191K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 7,494 | $12.75 | $95.5K | Form 4 |
| Dec 8, 2025 | Aik Na Tan | Director | Sale | 7,494 | $15.00 | $112K | Form 4 |
| Dec 8, 2025 | Gregory L. Verdine | Director | Sale | 12,020 | $13.09 | $157K | Form 4 |
| Dec 8, 2025 | Gregory L. Verdine | Director | Sale | 7,980 | $14.05 | $112K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 22,500 | $14.08 | $317K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 28,125 | $14.50 | $408K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 107,400 | $14.56 | $1.6M | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 45,882 | $14.50 | $665K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 9,375 | $15.00 | $141K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 37,500 | $14.08 | $528K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 17,900 | $15.00 | $268K | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 122,349 | $14.20 | $1.7M | Form 4 |
| Dec 8, 2025 | Chris Francis | See Remarks | Sale | 50,000 | $16.00 | $800K | Form 4 |
| Dec 8, 2025 | Kyle Moran | CFO | Sale | 60,000 | $13.20 | $792K | Form 4 |
| Dec 8, 2025 | Kyle Moran | CFO | Sale | 50,000 | $13.20 | $660K | Form 4 |
| Dec 8, 2025 | Kyle Moran | CFO | Sale | 50,000 | $15.00 | $750K | Form 4 |
| Dec 8, 2025 | Kyle Moran | CFO | Sale | 50,000 | $18.00 | $900K | Form 4 |
| Dec 8, 2025 | Mark Corrigan | Director | Sale | 9,600 | $13.09 | $126K | Form 4 |
| Dec 8, 2025 | Mark Corrigan | Director | Sale | 6,515 | $14.07 | $91.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ra Capital Management, L.P. | Director, 10% owner | $54.6M | – | Mar 30, 2026 |
| GSK plc | 10% owner | $27.9M | – | Dec 11, 2025 |
| Chris Francis | See Remarks | – | $7.1M | Feb 26, 2026 |
| Kyle Moran | Chief Financial Officer | – | $4.2M | Feb 9, 2026 |
| Aik Na Tan | Director | – | $1.6M | Aug 11, 2026 |
| Christian O Henry | Director | – | $1.4M | Dec 8, 2025 |
| Adrian Rawcliffe | Director | – | $697K | Aug 12, 2026 |
| Gregory L. Verdine | Director | – | $269K | Dec 8, 2025 |
| Heidi L Wagner | Director | – | $231K | Aug 11, 2026 |
| Mark Corrigan | Director | – | $217K | Dec 8, 2025 |
| Paul Bolno | President and CEO, Director | – | $141K | Feb 9, 2026 |
| Chandra Vargeese | See Remarks | – | $43.4K | Feb 9, 2026 |
| Ken Takanashi | Director | – | $23.2K | Aug 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
WVE short interest
High short interest. 10.5% of WVE shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 16%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 20.65M WVE shares were sold short, 10.5% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 3.06M shares, buying them all back would take about 6.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 20.65M | 10.47% | -2% | 3.06M | 6.8 |
| Oct 15, 2026 | 21.17M | 10.74% | +14% | 3.24M | 6.5 |
| Sep 30, 2026 | 18.56M | 9.42% | +5% | 3.26M | 5.7 |
| Sep 15, 2026 | 17.64M | 8.95% | +8% | 3.41M | 5.2 |
| Aug 31, 2026 | 16.28M | 8.26% | +0% | 2.96M | 5.5 |
| Aug 14, 2026 | 16.20M | 8.22% | -1% | 3.69M | 4.4 |
| Jul 31, 2026 | 16.40M | 8.32% | -3% | 2.20M | 7.5 |
| Jul 15, 2026 | 16.85M | 8.76% | -19% | 2.67M | 6.3 |
| Jun 30, 2026 | 20.90M | 10.87% | +15% | 3.68M | 5.7 |
| Jun 15, 2026 | 18.15M | 9.44% | -2% | 3.25M | 5.6 |
| May 29, 2026 | 18.53M | 9.63% | +4% | 4.05M | 4.6 |
| May 15, 2026 | 17.77M | 9.24% | +6% | 4.28M | 4.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Wave Life Sciences company events
Wave Life Sciences filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 27, 2026.
- Oct 27, 2026ResultsReleased financial results. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 26, 2026VoteReported shareholder vote results. Filing
- May 18, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the title of the press release, the fourth paragraph, tenth paragraph, and eleventh paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial… Filing
- Apr 28, 2026ResultsReleased financial results. Filing
- Apr 21, 2026AnnouncementWave Life Sciences Ltd. issued a press release entitled “Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States.” The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Filing
- Apr 15, 2026AgreementWave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore, announced that it has decided to restructure its corporate group to cause the parent company of the group to be a Delaware corporation. Filing
- Mar 26, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the second and the tenth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 2, 2026AnnouncementWave Life Sciences Ltd. issued a press release entitled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 11, 2025AgreementWave Life Sciences Ltd. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc., as representatives of the several underwriters named therein, relating to the issuance and sale in an underwritten public offering by the Company of an aggregate of… Filing
- Dec 8, 2025AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the title of the press release, the third paragraph, sixth paragraph, including the graphic therein, and ninth paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form… Filing
- Nov 17, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Wave Life Sciences financials
Famous investors that hold WVE
7 of the 50 well-known investors we track reported holding WVE in their latest 13F filing. The largest position is Lee Ainslie's, worth $36M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | Q3 2026 | 9.72M | $36M | 0.3% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.19M | $8.1M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.53M | $5.7M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.14M | $4.2M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 809,532 | $3M | 0.0% | New |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 173,000 | $640K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 93,355 | $345K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named WVE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Maverick Capital, Ltd. | 13G/A | 0.0% |
| Nov 16, 2026 | Maverick Capital, Ltd. | 13G/A | 0.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 6.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 6.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 0.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 0.0% |
Questions about Wave Life Sciences, Inc. (WVE) stock
Who owns the most WVE stock?
The largest reported owner of Wave Life Sciences, Inc. (WVE) is Ra Capital Management, L.P., with 14.0% of the company. In total, 237 funds and institutions reported holding WVE at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are WVE insiders buying or selling?
In the last 12 months, WVE insiders reported 5 open-market purchases worth $82.6M and 45 sales worth $15.8M. The latest trade was on Aug 12, 2026. See every trade.
What is the short interest in WVE?
As of Oct 30, 2026, 20.65M WVE shares were sold short, 10.5% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 3.06M shares, buying them all back would take about 6.8 trading days (days to cover). See the history.
Which famous investors hold WVE?
7 of the 50 well-known investors we track reported WVE in their latest 13F filing, including Lee Ainslie, Jim Simons, Ken Griffin. The largest position is worth $36M. See all holders.
Executive pay
Wave Life Sciences's chief executive was paid a total of $12.3M for the year ended Dec 31, 2025, up 187% from $4.3M the year before. In the last 12 months, Wave Life Sciences's executives and directors bought no stock on the open market and sold $15.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.